Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Hezkue and Hezkue Turbo Sildenafil Formulations
NCT07117383Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP-001 in erectile dysfunction (ED) (2 arms), sponsored by Aspargo Laboratories. Primary endpoints: Time to Maximum Observed Plasma Concentration of Sildenafil at 4 hours and Maximum Observed Plasma Concentration of Sildenafil at 4 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ASP-001
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT07117383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117383.